Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AdociaLTS:0QAI +6.57%33 Days Sales Outstanding is 1,699.22 as of Dec. 2025, which is 3252% above its 10-year median of 50.69. GuruFocus rates LTS:0QAI with a GF Score™ of 33/100 and a GF Value™ of €0.85 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 841 Biotechnology companies, Adocia ranks worse than 98.69% on this metric.
Adocia's average Accounts Receivable for the
six
months ended in Dec. 2025 was €4.13 Mil. Adocia's Revenue for the
six
months ended in Dec. 2025 was €0.44 Mil.
Hence, Adocia's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 1,699.22.
The historical rank and industry rank for Adocia's Days Sales Outstanding or its related term are showing as below:
LTS:0QAI'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.13 Med: 50.69 Max: 4213.11
Current: 4213.11
During the past 13 years, Adocia's highest Days Sales Outstanding was 4213.11. The lowest was 0.13. And the median was 50.69.
LTS:0QAI's Days Sales Outstanding is ranked worse than 98.69% of 841
companies
in the Biotechnology industry
Industry Median: 68.98
vs LTS:0QAI: 4213.11
Adocia's Days Sales Outstanding
increased
from Dec. 2024 (84.20) to Dec. 2025 (1,699.22).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
Adocia (LTS:0QAI) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Adocia Days Sales Outstanding Related Terms
Adocia Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Adocia's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0QAI vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Adocia's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adocia Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adocia's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Adocia's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 1,699.22 mean?
Adocia (LTS:0QAI) has a Days Sales Outstanding of 1,699.22 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Adocia and its competitors. This is 3252% above median its historical median of 50.69. Over the past decade, Adocia's Days Sales Outstanding has ranged from 0.13 to 4,213.11. According to the industry distribution chart, Adocia ranks #830 out of 841 companies in the Biotechnology industry, placing it in the top 98.7%.
Is Adocia's Days Sales Outstanding too high?
Adocia's current Days Sales Outstanding of 1,699.22 is 3252% above median its 10-year median of 50.69. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 4,213.11. The Biotechnology industry median Days Sales Outstanding is 68.98. Adocia's value of 1,699.22 is 2363.4% above this industry median. Based on the distribution chart, Adocia ranks #830 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Adocia has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adocia's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Adocia ranks #830 out of 841 companies for Days Sales Outstanding. This places Adocia in the lower half of its industry. The industry median Days Sales Outstanding is 68.98. Adocia's value of 1,699.22 is 2363.4% above this benchmark. Historically, Adocia's own Days Sales Outstanding has ranged from 0.13 to 4,213.11 over the past decade. While the company's 10-year median is 50.69 vs. the industry median of 68.98, Adocia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adocia's current Days Sales Outstanding of 1,699.22 is 2363.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Adocia and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adocia's current Days Sales Outstanding is 1,699.22, which is 3252% above median its own 10-year median of 50.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adocia stock overvalued right now?
Based on GuruFocus' analysis, Adocia (LTS:0QAI) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.85, compared to a current price of €3.73 — trading 338.8% above its estimated fair value. The current Days Sales Outstanding is 1,699.22, which is 3252% above median its 10-year median of 50.69 and 2363.4% above the Biotechnology industry median of 68.98. Adocia's overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Adocia (LTS:0QAI), the current Days Sales Outstanding is 1,699.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adocia (LTS:0QAI) Overvalued in 2026?
Based on GuruFocus' analysis, Adocia stock appears to be overvalued.
The current stock price of €3.73 is trading 338.8% above its estimated GF Value™ of €0.85.
GuruFocus considers Adocia to be Significantly Overvalued.
Key valuation signals for LTS:0QAI:
Days Sales Outstanding: 1,699.22 (3252% above median its 10-year median of 50.69)
GF Value™: €0.85 vs. price of €3.73 (338.8% above fair value)
Industry Position: 2363.4% above the Biotechnology median (#830 of 841)
No single metric tells the full story. See the LTS:0QAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
33GF Score
Get the complete analysis for LTS:0QAI
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QAI has been successfully added to your 
